Plasma biomarkers identify brain ATN abnormalities in a dementia-free population-based cohort
Menayit Tamrat Dresse, Pâmela C.L. Ferreira, Akshay Prasadan, Jihui L. Diaz, Xuemei Zeng, Bruna Bellaver, Guilherme Povala, Victor L. Villemagne, M. Ilyas Kamboh, Ann D. Cohen, Tharick A. Pascoal, Mary Ganguli, Beth E. Snitz, C. Elizabeth Shaaban, Thomas K. Karikari
Abstract
INTRODUCTION: Using the ATN framework, we evaluated the potential of plasma biomarkers to identify abnormal brain amyloid-beta (Aβ) positron emission tomography (PET), tau-PET and neurodegeneration in a socioeconomically disadvantaged population-based cohort. METHODS: Community-dwelling dementia-free (n = 113, including 102 (91%) cognitively normal) participants underwent ATN neuroimaging and plasma biomarker assessments. RESULTS: , respectively (p-values < 0.05), with p-tau217 demonstrating the highest classification accuracy for Aβ-PET status (AUC = 0.94). Plasma p-tau181 and p-tau217 showed significant associations with tau-PET status (AOR: 1.50 and 22.24, respectively (p-values < 0.05), with comparable classification accuracies for tau-PET status (AUC = 0.74 and 0.70, respectively). Only plasma NfL showed significant association with neurodegeneration based on cortical thickness (AOR = 1.09, p-value < 0.05). CONCLUSION: Our findings highlight the potential of plasma p-tau217 as a biomarker for brain Aβ and tau pathophysiology, p-tau181 for tau abnormalities, and NfL for neurodegeneration in the community.